MGMT启动子甲基化的范围、模式及预后价值:在胶质母细胞瘤与IDH野生型/TERT突变型星形细胞瘤之间是否存在差异?
该研究对比组织病理学诊断的胶质母细胞瘤与IDH野生型伴TERT启动子突变的星形细胞瘤,分析MGMT启动子甲基化范围与模式及预后价值。两组甲基化肿瘤数量及CpG位点甲基化模式无差异,放疗或化疗后无进展生存期与总生存期相似,两组中甲基化CpG位点数越多均与更有利结局相关。作者认为需在更大前瞻性队列中评估。
要点
- 两组间PCR检测的MGMT甲基化肿瘤数量无差异
- 两组间Sanger测序的甲基化CpG位点数量与模式无差异
- 两组中甲基化CpG位点数越多均与更有利结局相关
核心结论
- 胶质母细胞瘤与IDH野生型伴pTERT突变星形细胞瘤的甲基化CpG位点范围与模式相似。
- 两种肿瘤中,甲基化CpG位点数越多似乎与更有利结局相关。
- 作者认为需在更大前瞻性队列中评估。
研究设计与样本
- 研究检索机构数据库,纳入组织病理学诊断的胶质母细胞瘤患者及IDH野生型伴pTERT突变星形细胞瘤患者。
- 共识别224例组织病理学诊断的胶质母细胞瘤患者和54例IDH野生型伴pTERT突变星形细胞瘤患者(19例WHO II级星形细胞瘤和38例WHO III级星形细胞瘤)。
- 采用甲基化特异性PCR和Sanger测序分析MGMT启动子区域CpG位点甲基化。
主要发现
- 按PCR检测,两组队列间MGMT甲基化肿瘤数量无差异。
- 按Sanger测序,两组间甲基化CpG位点数量及模式均无差异。
- 接受放疗或化疗时,两组队列的无进展生存期和总生存期相似。
- 两组队列中,较高甲基化CpG位点数均与更有利结局相关。
局限性
- 作者认为需在更大前瞻性队列中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The cIMPACT-NOW update 6 first introduced glioblastoma diagnosis based on the combination of IDH-wildtype (IDHwt) status and TERT promotor mutation (pTERTmut). In glioblastoma as defined by histopathology according to the WHO 2016 classification, MGMT promotor status is associated with outcome. Whether this is also true in glioblastoma defined by molecular markers is yet unclear. METHODS: We searched the institutional database for patients with: (1) glioblastoma defined by histopathology; and (2) IDHwt astrocytoma with pTERTmut. MGMT promotor methylation was analysed using methylation-specific PCR and Sanger sequencing of CpG sites within the MGMT promotor region. RESULTS: We identified 224 patients with glioblastoma diagnosed based on histopathology, and 54 patients with IDHwt astrocytoma with pTERTmut (19 astrocytomas WHO grade II and 38 astrocytomas WHO grade III). There was no difference in the number of MGMT methylated tumors between the two cohorts as determined per PCR, and also neither the number nor the pattern of methylated CpG sites differed as determined per Sanger sequencing. Progression-free (PFS) and overall survival (OS) was similar between the two cohorts when treated with radio- or chemotherapy. In both cohorts, higher numbers of methylated CpG sites were associated with favourable outcome. CONCLUSIONS: Extent and pattern of methylated CpG sites are similar in glioblastoma and IDHwt astrocytoma with pTERTmut. In both tumor entities, higher numbers of methylated CpG sites appear associated with more favourable outcome. Evaluation in larger prospective cohorts is warranted.
引用
- Teske N, Karschnia P, Weller J, et al. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma? J Neurooncol. 2021. PMID: 34902093. doi:10.1007/s11060-021-03912-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。